Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition, pharmaceutical preparation and application

A composition and pharmacy technology, applied in the field of medicine, can solve the problems such as the lack of safe and effective prevention of cardiovascular and cerebrovascular diseases.

Inactive Publication Date: 2019-09-17
武汉圣朗生物工程有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, there is no product on the market that can safely and effectively prevent cardiovascular and cerebrovascular diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition, pharmaceutical preparation and application
  • Composition, pharmaceutical preparation and application
  • Composition, pharmaceutical preparation and application

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0037] The preparation method of the pharmaceutical composition / pharmaceutical preparation of each example, comprises the following steps:

[0038] (1) Add ginsenoside Rg2, orientin, taurine, soybean lecithin and PVPK30 into ethanol in sequence, and stir to dissolve; (2) Dry under reduced pressure under stirring until it is a viscous liquid, add cross-linked polyvinylpyrrolidone Mix evenly, and continue to dry under reduced pressure until absolute ethanol is removed to obtain the product.

Embodiment 1

[0039] The influence of embodiment 1 composition on rat blood fat and blood viscosity

[0040] In this experiment, the effect of the composition on blood lipid and blood viscosity of rats was tested to confirm that the composition has obvious effects of lowering blood fat and blood viscosity, and that the combined effect is obviously better than that of each component used alone.

[0041] 1. Experimental method

[0042] 1.1 Animals and grouping Select 48 SD rats, half male and half female, weighing 200-220g, and after a week of balanced diet, they are randomly divided into 6 groups with 8 rats in each group, which are blank control group (A) and high-fat diet group ( B), high-fat feed ginsenoside Rg2 group (C), high-fat feed orientin group (D), high-fat feed taurine group (E) and high-fat feed combination group (F), high-fat feed combination Tablet group (G) and high-fat feed composition liposome group (H). Wherein group A was fed with basic feed and given 0.9% sodium chlori...

Embodiment 2

[0055] Example 2 The protective effect of the composition on oxidative stress damage of human umbilical vein endothelial cells

[0056] Use H 2 o 2 Inducing human umbilical vein endothelial cells (HUVEC) to establish an injury model in vitro, the purpose is to test the protective effect of the composition on cells and its antioxidant effect.

[0057] 1. Experimental method:

[0058] 1.1 Cell culture and grouping HUVECs were revived and passaged in RPMI-1640 medium containing 10% NBS, inoculated in 25mL culture flasks, and incubated at 37°C and 5% CO 2 : Static cultivation in an incubator. Cells were randomly divided into normal control group, H 2 o 2 group, Rg2 group, orientin group, taurine group and combination group. The cells in the normal control group were only cultured with serum-free medium without any drug treatment; H2 o 2 The group was pre-cultured with serum-free medium for 24 hours, and after the medium was changed, it was added with 400 μmol / LH 2 o 2 Rg2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses a composition, a pharmaceutical preparation and an application. The composition comprises 1-5 parts by mass of ginsenoside Rg2,10-20 parts by mass of at least one of bamboo-leaves flavones, orientoside, Isoorientin, agnoside and isovitexin, and 15-25 parts by mass of taurine or pharmaceutically acceptable salt thereof. The composition can effectively prevent and / or treat cardiovascular and cerebrovascular diseases.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to a composition, a pharmaceutical preparation and the use of the composition and / or the pharmaceutical preparation. Background technique [0002] Cardiovascular and cerebrovascular diseases are collectively referred to as cardiovascular and cerebrovascular diseases. disease. Cardiovascular and cerebrovascular disease is a common disease that seriously threatens the health of human beings, especially middle-aged and elderly people over 50 years old. It has the characteristics of high prevalence, high disability rate and high mortality rate. However, there are still more than 50% of cerebrovascular accident survivors who cannot take care of themselves completely. The number of cardiovascular and cerebrovascular diseases in the world is as high as 15 million people every year, ranking first among various causes of death. At present, the number of patients with cardiovascular and cere...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K31/185A61K31/352A61P9/10A61P9/00A61P9/12A61P3/06
CPCA61K31/185A61K31/352A61K31/704A61P3/06A61P9/00A61P9/10A61P9/12A61K2300/00
Inventor 易以木
Owner 武汉圣朗生物工程有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com